申请人:Mochida Pharmaceutical Co., Ltd.
公开号:US20020188006A1
公开(公告)日:2002-12-12
The present invention relates to a compound represented by the following formula (I) or a salt thereof, or a pharmaceutical composition containing the compound as an effective ingredient:
1
(wherein A represents, for example, phenyl group substituted with R
1
and R
2
or unsubstituted thienyl group; R
1
and R
2
each independently represent, for example, hydrogen atom, halogen atom or lower alkoxycarbonyl group; R
3
represents, for example, hydrogen atom; R
4
represents, For example, lower alkyl group; R
5
represents, for example, lower alkoxy group; R
6
represents, for example, hydrogen atom; R
7
and R
8
each represent, for example, hydrogen atom, respectively; X represents, for example, a single bond; Y represents, for example, methylene group or benzylidene group substituted with R
1
; and Z represents, for example, methylene group.) The compounds according to the present invention that do not suppress the transient sodium current of the cardiac muscle and do not manifest proarrhythimic activity is useful as a therapeutic agent for preventing and/or treating arrhythimia and for preventing sudden death.
本发明涉及以下式(I)所表示的化合物或其盐,或含有该化合物作为有效成分的药物组合物:1(其中A代表例如被R1和R2取代的苯基或未被取代的
噻吩基;R1和R2各自独立地代表例如氢原子、卤素原子或低
碳酸酯基;R3代表例如氢原子;R4代表例如低烷基基团;R5代表例如低烷氧基团;R6代表例如氢原子;R7和R8各自代表例如氢原子;X代表例如单键;Y代表例如被R1取代的亚甲基基团或苄亚甲基基团;以及Z代表例如亚甲基基团。)本发明的化合物不抑制心肌瞬时
钠电流,也不表现出致心律失常活性,因此可用作预防和/或治疗心律不齐和预防猝死的治疗剂。